Status:
COMPLETED
The Effect of Eprosartan on Hormones and Kidney Function in Healthy Humans.
Lead Sponsor:
Regional Hospital Holstebro
Conditions:
Healthy
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
We, the investigators at Holstebro Hospital, want to test the hypothesis that eprosartan reduces the activity of the sympathetic nervous system in healthy individuals - during baseline conditions and ...
Eligibility Criteria
Inclusion
- Both genders.
- Age 18 - 65 years.
- Body mass index less or equal to 30 kg/m2.
- Women must use oral hormonal anticonception, use intrauterine anticonceptive device, be sterilized/hysterectomized or be postmenopausal.
Exclusion
- History or clinical signs of heart, lung, kidney, or endocrine organ disease.
- Abnormal biochemical screening of the blood regarding: B-hemoglobin, P-sodium, P-potassium, P-creatinine, P-albumin, P-bilirubin, P-alanine aminotransferase, P-alkaline phosphatase, P-cholesterol, and B-glucose.
- Abnormal screening of the urine regarding: albumin and glucose
- Malignant disease.
- Known arterial hypertension or measured 24 hour blood pressure above 135 mmHg systolic or 85 mmHg diastolic.
- Alcohol abuse.
- Smoking.
- Drug use or abuse.
- Known intolerance or allergy to eprosartan or sodium nitroprusside.
- Blood donation within 1 month of the start of the study.
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00409903
Start Date
November 1 2006
Last Update
September 14 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Medical Research, Holstebro Hospital
Holstebro, Denmark, 7500